Amgen, Watson will develop follow-on biologics for cancer

12/19/2011 | Wall Street Journal, The

Amgen will team up with Watson Pharmaceuticals to develop and commercialize follow-on versions of several antibody biotech drugs for cancer, excluding Amgen's products. Amgen will be in charge of development, production and initial marketing. Watson will provide as much as $400 million for product development and contribute its commercialization and marketing know-how.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY